长沙定邦医药科技

Changsha Dingbang Medical Technology Co., Ltd. was a Chinese pharmaceutical company founded in 2002 and based in Changsha, Hunan Province. The company focused on the development of traditional Chinese medicines (TCM), with its primary pipeline candidate being Gengnian Anshen Capsule (更年安神胶囊) for the treatment of menopausal syndrome (specifically the kidney yin-yang deficiency syndrome). The candidate reached Phase 3 clinical trials (CTR20132960) in China, which was conducted in collaboration with Hunan Anbang Pharmaceutical. However, the clinical development was ultimately terminated, and the company has since been deregistered (注销).